Will AAV provide gene therapy with a safer, more efficient delivery vehicle?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
McKeon, C. and Samulski, R.J. 1996. Hum. Gene Ther. 7: 1615–1619.
Flotte. T. et al. 1996. Fed. Pulmonol., Suppl. 13: 275.
Wagner, J.A. et al. 1996. Ped. Pulmonol., Suppl. 13: 276.
Flotte, T. and Carter, B.J. 1995. Gene Therapy 2: 357–362.
Afione, S.A. et al. 1996. J. Virol. 70: 3235–3241.
Alexander, I.E. et al. 1994. J. Virol. 68: 8282–8287.
Ferrari, F.K. et al. 1996. J. Virol. 70: 3227–3234.
Fisher, K.J., et al. 1996. J. Virol. 70: 520–523.
Conrad, C.K. et al. Gene Therapy 3: 658–668.
Xiao X. et al. 1996. J. Virol. 70: 8098–8108.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carter, B. The promise of adeno-associated virus vectors. Nat Biotechnol 14, 1725–1726 (1996). https://doi.org/10.1038/nbt1296-1725
Issue Date:
DOI: https://doi.org/10.1038/nbt1296-1725
This article is cited by
-
Macromolecular cytosolic delivery: Cell membranes as the primary obstacle
Archives of Pharmacal Research (1998)